ACRV Acrivon Therapeutics, Inc.
Nasdaq · SEC CIK 1781174 · EDGAR
- Bought, last 12 months
- $114.5K 3 purchases by 3 insiders
- Sold, last 12 months
- $39.8K 9 sales by 6 insiders
- Filings on record
- 182 since 2022-11-16, latest 2026-09-02 16:30
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Blume-Jensen Peter | Pres, CEO, Dir | $82.3K | $34.4K |
| Devroe Eric | COO | $17.2K | $1,214 |
| Levy Adam D. | CFO | $15.0K | $1,793 |
| Miller Mary | CLO | — | $1,380 |
| Gamelin Erick | Chief Development Off | — | $804.00 |
| Peterson Katharine | CAO | — | $203.01 |
| Levin Michaela | Chief Business Off | — | — |
| Palani Santhosh | Dir | — | — |
| Masson Kristina | EVP - Business Ops, Dir | — | — |
| DiRocco Derek | Dir | — | — |
Transactions 146
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-19 | 2024-07-17 | ACRV | Miller Mary | CLO | F - Tax | $7.69 | -558 | 39.2K | -1% | -$4,291 | |
| D | 2024-05-21 | 2024-05-17 | ACRV | Devroe Eric | COO | M - OptEx | $1.04 | +10.0K | 69.1K | +17% | +$10.4K |
| 2024-05-16 | 2024-05-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $8.36 | -54.9K | 2.56M | -2% | -$459.1K | |
| 2024-05-16 | 2024-05-14 | ACRV | Devroe Eric | COO | F - Tax | $8.36 | -613 | 59.1K | -1% | -$5,125 | |
| 2024-05-16 | 2024-05-14 | ACRV | Masson Kristina | EVP - Business Ops, Dir | F - Tax | $8.36 | -490 | 317.7K | -0.2% | -$4,096 | |
| 2024-05-16 | 2024-05-14 | ACRV | Peterson Katharine | CAO | F - Tax | $8.36 | -99 | 4,733 | -2% | -$827.64 | |
| 2024-05-16 | 2024-05-14 | ACRV | Gamelin Erick | Chief Development Off | F - Tax | $8.36 | -402 | 17.8K | -2% | -$3,361 | |
| 2024-05-16 | 2024-05-14 | ACRV | Miller Mary | CLO | F - Tax | $8.36 | -184 | 39.7K | -0.5% | -$1,538 | |
| 2024-05-16 | 2024-05-14 | ACRV | Holm-Jorgensen Rasmus | CFO | F - Tax | $8.36 | -368 | 27.3K | -1% | -$3,076 | |
| 2024-04-19 | 2024-04-17 | ACRV | Miller Mary | CLO | F - Tax | $10.34 | -558 | 39.9K | -1% | -$5,770 | |
| I | 2024-04-15 | 2024-04-11 | ACRV | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | 10% | P - Purchase | $8.50 | +2.35M | 5.36M | +78% | +$20.00M |
| I | 2024-04-15 | 2024-04-11 | ACRV | RA Capital Healthcare Fund LP | Dir, 10% | A - Grant | $8.50 | +3.53M | 7.91M | +81% | +$30.00M |
| 2024-02-16 | 2024-02-14 | ACRV | Gamelin Erick | Chief Development Off | F - Tax | $3.40 | -468 | 18.2K | -3% | -$1,591 | |
| 2024-02-16 | 2024-02-14 | ACRV | Masson Kristina | EVP - Business Ops, Dir | F - Tax | $3.40 | -579 | 318.2K | -0.2% | -$1,969 | |
| 2024-02-16 | 2024-02-14 | ACRV | Holm-Jorgensen Rasmus | CFO | F - Tax | $3.40 | -434 | 27.6K | -2% | -$1,476 | |
| 2024-02-16 | 2024-02-14 | ACRV | Devroe Eric | COO | F - Tax | $3.40 | -723 | 59.7K | -1% | -$2,458 | |
| 2024-02-16 | 2024-02-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $3.40 | -41.9K | 2.62M | -2% | -$142.3K | |
| 2024-02-16 | 2024-02-14 | ACRV | Miller Mary | CLO | F - Tax | $3.40 | -217 | 40.5K | -0.5% | -$737.80 | |
| 2024-01-19 | 2024-01-17 | ACRV | Miller Mary | CLO | F - Tax | $4.35 | -652 | 40.7K | -2% | -$2,836 | |
| 2023-11-16 | 2023-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $5.08 | -239.0K | 2.66M | -8% | -$1.21M | |
| 2023-11-16 | 2023-11-14 | ACRV | Devroe Eric | COO | F - Tax | $5.08 | -2,450 | 60.4K | -4% | -$12.4K | |
| 2023-11-16 | 2023-11-14 | ACRV | Masson Kristina | EVP - Business Ops, Dir | F - Tax | $5.08 | -1,900 | 318.8K | -0.6% | -$9,652 | |
| 2023-11-16 | 2023-11-14 | ACRV | Holm-Jorgensen Rasmus | CFO | F - Tax | $5.08 | -1,470 | 28.1K | -5% | -$7,468 | |
| 2023-11-16 | 2023-11-14 | ACRV | Gamelin Erick | Chief Medical Off | F - Tax | $5.08 | -1,395 | 18.6K | -7% | -$7,087 | |
| 2023-11-16 | 2023-11-14 | ACRV | Miller Mary | CLO | F - Tax | $5.08 | -735 | 41.3K | -2% | -$3,734 | |
| 2023-10-19 | 2023-10-17 | ACRV | Miller Mary | CLO | F - Tax | $5.48 | -2,232 | 42.1K | -5% | -$12.2K | |
| D | 2023-09-28 | 2023-09-26 | ACRV | Miller Mary | CLO | A - Grant | $0.00 | +3,858 | 44.3K | +10% | $0 |
| 2023-08-23 | 2023-08-21 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +494.0K | 2.90M | +21% | $0 | |
| 2023-06-28 | 2023-06-26 | ACRV | Smolokowski Wiaczeslaw | 10% | S - Sale | $12.93 | -16 | 3.85M | -0.0% | -$206.88 | |
| 2023-06-20 | 2023-06-15 | ACRV | Nikolaou Anastasis | 10% | S - Sale | $12.14 | -2,056 | 3.85M | -0.1% | -$25.0K | |
| D | 2023-06-20 | 2023-06-16 | ACRV | Holm-Jorgensen Rasmus | CFO | M - OptEx | $3.63 | +9,500 | 29.5K | +47% | +$34.5K |
| M | 2023-06-14 | 2023-06-12+ | ACRV | Chione Ltd | 10% | S - Sale | $12.29 | -5,893 | 3.85M | -0.2% | -$72.4K |
| D | 2023-06-06 | 2023-06-05 | ACRV | Devroe Eric | COO | M - OptEx | $1.04 | +9,225 | 62.9K | +17% | +$9,594 |
| D | 2023-06-01 | 2023-05-31 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | M - OptEx | $3.88 | +33.6K | 2.40M | +1% | +$130.4K |
| DMI | 2022-11-21 | 2022-11-17 | ACRV | RA Capital Healthcare Fund LP | Dir, 10% | C - Cnv Deriv | — | +1.42M | 994.7K | New | — |
| DI | 2022-11-21 | 2022-11-17 | ACRV | RA Capital Healthcare Fund LP | Dir, 10% | P - Purchase | $12.50 | +3.39M | 4.38M | +341% | +$42.37M |
| D | 2022-11-21 | 2022-11-17 | ACRV | Hadjimichael Andreas | 10% | P - Purchase | $12.50 | +400.0K | 3.86M | +12% | +$5.00M |
| DM | 2022-11-21 | 2022-11-17 | ACRV | Hadjimichael Andreas | 10% | C - Cnv Deriv | — | +3.46M | 3.86M | +864% | — |
| D | 2022-11-21 | 2022-11-17 | ACRV | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | — | +888.1K | 888.1K | New | — |
| D | 2022-11-16 | 2022-11-14 | ACRV | Gamelin Erick | Chief Medical Off | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| D | 2022-11-16 | 2022-11-14 | ACRV | Holm-Jorgensen Rasmus | CFO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| DMI | 2022-11-16 | 2022-11-14 | ACRV | Masson Kristina | EVP - Business Ops, Dir | A - Grant | $0.00 | +1.50M | 2.31M | +185% | $0 |
| D | 2022-11-16 | 2022-11-14 | ACRV | Masson Kristina | EVP - Business Ops, Dir | A - Grant | $0.00 | +26.7K | 320.7K | +9% | $0 |
| DM | 2022-11-16 | 2022-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +1.50M | 2.37M | +172% | $0 |
| DI | 2022-11-16 | 2022-11-14 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +26.7K | 320.7K | +9% | $0 |
| D | 2022-11-16 | 2022-11-14 | ACRV | Devroe Eric | COO | A - Grant | $0.00 | +33.4K | 53.7K | +165% | $0 |
Purchase Sale Sale after option exercise All abbreviations